Cilostazol

( DrugBank: Cilostazol / KEGG DRUG: Cilostazol )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
46Malignant rheumatoid arthritis2
51Scleroderma1

6. Parkinson disease


Clinical trials : 2,586Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 639Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

70. Spinal stenosis


Clinical trials : 127Drugs : 178 - (DrugBank : 67) / Drug target genes : 87 - Drug target pathways : 99 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy


Clinical trials : 17Drugs : 19 - (DrugBank : 9) / Drug target genes : 6 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries